Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
EyePoint Pharmaceuticals, Inc.
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adults 18 through 80 years of age (inclusive)
Subjects with moderate to very severe NPDR (ETDRS Level 43 - 53 inclusive)
No evidence of central involved diabetic macular edema
ETDRS best-corrected visual acuity letter score ≥ 70 (Snellen 20/40 or better)
You may not be if
Ocular disease other than DR that may cause substantial reduction in visual acuity, including iris neovascularization, retinal detachment, visually significant epiretinal membrane, vitreous hemorrhage or fibrosis, ocular inflammation (uveitis), other retinal inflammatory or infectious diseases
Evidence of neovascularization on clinical examination or imaging
Hemoglobin A1C (HbA1C) ≥ 12.0% at Screening
Severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation
Clareo Health | The TIME-2b Study: A Study of AKB-9778 (Razuprotafib), a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)
